Scientists have studied the beneficial effects of P2Y11 (a potential receptor) that obstructs rheumatoid arthritis (RA). P2Y11 is a sub type of purinergic receptors that alters the function of immune cells1.
Rheumatoid arthritis is an auto-immune disorder differentiated by obliteration of bone and cartilage. All over the world around 1% of people are suffering from RA2. Constant- inflammation of joint develops the arthritis, due to penetration of inflammatory cells and also the immune cells like neutrophils, macrophages, B and T-cells3.
Many therapies are existing for treating arthritis including; disease modifying anti-rheumatic drugs, biological therapy and glucocorticoids4.
There are several therapies available for the management of RA such as. Nonetheless these drugs are expensive and entails the constant use of it these treatments may cause many bad effects. Hence, a new curative treatment is requisite for the management of arthritis and immune system.
The receptor P2Y11 is present on many immune cells as; lymphocytes, mast cells, granulocytes and dendrite cells5. Cellular immune system is modulated by these receptors moreover they also induce the movement and differentiation of immune cells. So this led the scientists to study these receptors in detail with focus on their effects against the Rheumatoid Arthritis.
Researchers induced the arthritis in experimental animals. P2Y11 receptor was blocked by P2Y11 receptor antagonist (NF340). The experimental animals were divided into 5 groups having different treatments accordingly. Development of RA was estimated by arthritic score, paw swelling and paw withdrawal latency. Pro-inflammatory cytokines in the synovial fluid, anti-type II collagen antibodies in serum and proliferation of T-cell was estimated in RA rats.
Study authors said:
“Our investigation proves that gene expression of P2Y11 receptor blocked by NF340 attenuates the RA by ameliorating the cellular and humoral immunity. Moreover alteration in the cellular and humoral immunity reduces the level of inflammatory cytokines in NF340 treated groups.”
The blocking of P2Y11 receptor could be a good target for the management of Rheumatoid arthritis. Further studies are required to explore the in depth mechanism involved in this phenomena.
Written by: Rabeeia
Your email address will not be published. Required fields are marked *
17 November, 2019